abs298.txt	purpose		the	ongoing	opioid	epidemic	has	claimed	more	than	a	quarter	millionamericans'	lives	over	the	past	15	years		the	epidemic	began	with	an	escalation	ofprescription	opioid	deaths	and	has	now	evolved	to	include	secondary	waves	ofillicit	heroin	and	fentanyl	deaths		while	the	deaths	due	to	prescription	opioidoverdoses	are	still	increasing		in	response		the	centers	for	disease	control	andprevention	(cdc)	moved	to	limit	opioid	prescribing	with	the	release	of	opioidprescribing	guidelines	for	chronic	noncancer	pain	in	march	2016		the	guidelinesrepresent	a	logical	and	timely	federal	response	to	this	growing	crisis		however	cdc	acknowledged	that	the	evidence	base	linking	opioid	prescribing	to	opioid	usedisorders	and	overdose	was	grades	3	and	4	methods		motivated	by	the	need	to	strengthen	the	evidence	base		this	reviewdetails	limitations	of	the	opioid	safety	studies	cited	in	the	cdc	guidelines	witha	focus	on	methodological	limitations	related	to	internal	and	external	validity	results		internal	validity	concerns	were	related	to	poor	confounding	control	variable	misclassification		selection	bias		competing	risks		and	potentialcompeting	interventions		external	validity	concerns	arose	from	the	use	of	limitedsource	populations		historical	data	(in	a	fast-changing	epidemic)		and	issueswith	handling	of	cancer	and	acute	pain	patients'	data		we	provide	a	nonexhaustivelist	of	7	recommendations	to	address	these	limitations	in	future	opioid	safetystudies	conclusion		strengthening	the	opioid	safety	evidence	base	will	aid	any	futurerevisions	of	the	cdc	guidelines	and	enhance	their	prevention	impact	
